NOMAD Bioscience Receives Notice of Allowance From USPTO for Its Patent Application 'Colicins for the control of EHEC'

(PresseBox) ( München, )
NOMAD has announced that the United States’ Patent and Trademark Office has issued the "Notice of Allowance" for the NOMAD’s patent application “Colicins for the control of EHEC”, U.S. Appl. No. 15/144,271. All filed claims of the application necessary for a broad protection have been allowed. This is the first issued U.S. patent that protects NOMAD’s Colicins, non-antibiotic antibacterial proteins and the company’s lead product candidates for food and feed safety market.

Enterohemorrhagic or Shiga toxin–producing Escherichia coli (EHEC) contaminating food products are a major cause of bacterial enteric infections in USA and worldwide. NOMAD product candidates described and claimed in the patent application are simple mixtures of two or more bacterial Colicins produced in plants and applied at very low concentrations; the products are highly and broadly active against all major pathogenic E. coli strains causing food poisoning defined by USDA/FSIS as requiring priority control (‚Big Seven‘).

‘We are very pleased that USPTO has allowed all essential claims in our submitted application’, said Prof. Dr. Yuri Gleba, NOMAD’s CEO. ‘Our Colicin product candidates have already received GRAS manufacturing regulatory approvals in USA from FDA or FDA/USDA as food additives and food processing aids (GRN 593, GRN 676 and GRN 775). These regulatory approvals, together with the broad patent protection and exclusivity resulting from the USPTO decision, significantly strengthens NOMAD’s position as the leading provider of novel safety solutions for food and feed market.’

In addition to Colicins, other plant-produced bacterial and bacteriophage Bacteriocins are being developed by NOMAD as inexpensive food additives and food processing aids for the broad control of most common bacterial pathogens (Escherichia coli, Salmonella enterica and Clostridium perfringens) in food products. NOMAD is also actively developing Bacteriocins as medical alternatives to antibiotics, with its pre-clinical research focused on novel antibacterial proteins for control of major multi-drug resistant Gram-negative pathogens including Escherichia, Pseudomonas and Klebsiella. NOMAD is aggressively filing for patent protection of all its inventions related to Bacteriocins as food additives and medicines.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an